Skip to main content
China Biotech Services Holdings Limited logo

China Biotech Services Holdings Limited — Investor Relations & Filings

Ticker · 8037 ISIN · BMG2152F1014 HKEX Human health and social work activities
Open in API
Filings indexed 1,393 across all filing types
Latest filing 2026-05-22 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 8037

About China Biotech Services Holdings Limited

http://www.cbshhk.com

China Biotech Services Holdings Limited operates as an investment holding company with diversified interests primarily focused on the healthcare sector. The company's core activities include the provision of medical laboratory testing and comprehensive health check services, serving markets such as the People's Republic of China. Its operations encompass a pathology laboratory providing third-party medical testing, recognized as one of Hong Kong's largest providers in this domain, boasting a history of over 54 years. Furthermore, the company maintains a Pharmaceutical Products segment dedicated to the research, development, manufacture, sale, and distribution of health-related and pharmaceutical products. It also engages in investment activities, including real estate.

Recent filings

Filing Released Lang Actions
Notification Letter to Non-Registered Shareholders
Report Publication Announcement Classification · 90% confidence The document is a short shareholder notification letter informing non-registered shareholders that certain corporate communications (including a circular and notice of AGM) are available online, and advises how to request printed copies. It does not contain the actual financial or meeting materials, but merely announces their publication and availability. Under the “menu vs meal” rule, this is an announcement of report availability, not the reports themselves, and thus falls under Report Publication Announcement (RPA).
2026-05-22 English
Notification Letter to Registered Shareholders and Reply Form
Report Publication Announcement Classification · 87% confidence The document is a notification letter to shareholders informing them that certain corporate communications (a circular and proxy form for the AGM) have been published on the company’s and HKEX’s websites and providing a reply form for requesting printed copies or email notifications. It does not contain the underlying financial report or AGM materials themselves, but rather announces their availability. Under the “menu vs meal” rule, this is a report publication announcement, not the report itself.
2026-05-22 English
Form of proxy
Proxy Solicitation & Information Statement Classification · 99% confidence The document is a form of proxy for use by shareholders at the annual general meeting, which is a solicitation of votes/proxies. This clearly falls under Proxy Solicitation & Information Statement (materials sent to shareholders for voting), matching the PSI category.
2026-05-22 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 89% confidence The document is a formal "Notice of Annual General Meeting" for China Biotech Services Holdings Limited, detailing the time, place, proposed resolutions (including receipt of audited accounts, director re-elections, share repurchase mandate, share issuance mandate, etc.), proxy appointment procedures, and other logistical matters related to the upcoming AGM. It is neither the annual report itself nor the results of the vote, but a notice convening the AGM. This aligns with the definition of AGM Information (AGM-R).
2026-05-22 English
(1) PROPOSED GRANT OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; (2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITOR; AND (4) NOTICE OF ANNUAL GE
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a shareholder circular containing an explanatory statement and notice of the annual general meeting, including resolutions for share repurchase mandates, re-election of directors, re-appointment of auditors, and the form of proxy. It is clearly a proxy solicitation document sent ahead of an AGM, not the AGM materials themselves (AGM-R) or the result announcement (DVA), nor a full financial report. It thus fits the Proxy Solicitation & Information Statement category.
2026-05-22 English
MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF THE ENTIRE ISSUED SHARE CAPITAL IN PHC MEDICAL DIAGNOSTIC CENTRE LIMITED AND PREMIER MEDICARE SERVICES LIMITED
M&A Activity Classification · 85% confidence The document is a formal Hong Kong Exchange announcement by China Biotech Services Holdings Limited detailing the Sale and Purchase Agreement for the disposal of two subsidiaries, including the transaction structure, terms, consideration, conditions precedent and listing rule implications. This is an M&A transaction announcement (a major transaction under GEM Listing Rules), not an earnings release, report publication notice, or financial statement. Hence it falls under M&A Activity (Code: TAR).
2026-05-18 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.